Literature DB >> 2467190

Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes.

T F Tedder1, G McIntyre, S F Schlossman.   

Abstract

The B1 molecule (CD20) is a phosphoprotein expressed only by B-lymphocytes. In this study, analysis of B1 immunoprecipitated from surface iodinated B-cell lines and B-lymphocytes has shown that there are several expressed forms of B1. A predominant species of Mr 33,000 represents 75-80% of the iodinated cell surface B1 and a Mr 35,000 species represents 20-25%. Limited proteinase digestion of these two species generated similar peptide maps demonstrating that the different forms of B1 shared common peptides. Biosynthetic labeling with [35S]methionine revealed that the Mr 35,000 B1 species may actually represent two bands of Mr 34,500 and 36,000. Endoglycosidase digestion studies and metabolic labeling in the presence of tunicamycin indicated that neither the Mr 33,000 or 34,500-36,000 forms of B1 were glycosylated. The Mr 33,000 and 34,500-36,000 forms of B1 were constitutively phosphorylated in B-cell lines. However, exposure of B-cells to PMA resulted in a significant increase in the phosphorylation of the Mr 34,500-36,000 form. Exposure to PMA also resulted in an increase in the amount of Mr 34,500-36,000 protein immunoprecipitated from 35S labeled cells. These results suggest that there are multiple forms of the B1 molecule expressed by B-lymphocytes and that this heterogeneity may result from phosphorylation of the B1 protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2467190     DOI: 10.1016/0161-5890(88)90047-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy.

Authors:  Kuangshi Wu; Jiyuan Yang; Jihua Liu; Jindřich Kopeček
Journal:  J Control Release       Date:  2011-08-06       Impact factor: 9.776

2.  Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.

Authors:  B D Hock; G C Starling; P B Daniel; D N Hart
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

Review 3.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

Review 4.  Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Authors:  Rehana Z Hussain; Liat Hayardeny; Petra C Cravens; Felix Yarovinsky; Todd N Eagar; Benjamine Arellano; Krystin Deason; Cyd Castro-Rojas; Olaf Stüve
Journal:  J Neuroimmunol       Date:  2014-08-30       Impact factor: 3.478

5.  Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

Authors:  Russell N Johnson; Pavla Kopecková; Jindrich Kopecek
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

6.  Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.

Authors:  P Engel; N Wagner; A S Miller; T F Tedder
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

7.  Neonatally induced inactivation of the vascular cell adhesion molecule 1 gene impairs B cell localization and T cell-dependent humoral immune response.

Authors:  C E Leuker; M Labow; W Müller; N Wagner
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

8.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.

Authors:  J K Bubien; L J Zhou; P D Bell; R A Frizzell; T F Tedder
Journal:  J Cell Biol       Date:  1993-06       Impact factor: 10.539

9.  Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells.

Authors:  Yoshikazu Furusawa; Mika Kato Kaneko; Yukinari Kato
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.